Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 27;21(23):9036.
doi: 10.3390/ijms21239036.

Danger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer's Disease

Affiliations
Review

Danger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer's Disease

Anna Chiarini et al. Int J Mol Sci. .

Abstract

Fibrillar aggregates and soluble oligomers of both Amyloid-β peptides (Aβs) and hyperphosphorylated Tau proteins (p-Tau-es), as well as a chronic neuroinflammation are the main drivers causing progressive neuronal losses and dementia in Alzheimer's disease (AD). However, the underlying pathogenetic mechanisms are still much disputed. Several endogenous neurotoxic ligands, including Aβs, and/or p-Tau-es activate innate immunity-related danger-sensing/pattern recognition receptors (PPRs) thereby advancing AD's neuroinflammation and progression. The major PRR families involved include scavenger, Toll-like, NOD-like, AIM2-like, RIG-like, and CLEC-2 receptors, plus the calcium-sensing receptor (CaSR). This quite intricate picture stresses the need to identify the pathogenetically topmost Aβ-activated PRR, whose signaling would trigger AD's three main drivers and their intra-brain spread. In theory, the candidate might belong to any PRR family. However, results of preclinical studies using in vitro nontumorigenic human cortical neurons and astrocytes and in vivo AD-model animals have started converging on the CaSR as the pathogenetically upmost PRR candidate. In fact, the CaSR binds both Ca2+ and Aβs and promotes the spread of both Ca2+ dyshomeostasis and AD's three main drivers, causing a progressive neurons' death. Since CaSR's negative allosteric modulators block all these effects, CaSR's candidacy for topmost pathogenetic PRR has assumed a growing therapeutic potential worth clinical testing.

Keywords: Alzheimer’s disease; calcium signaling; danger-sensing receptors; inflammasomes; neuroinflammation; pattern recognition receptors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Top: A summary representation of the main cell types and proinflammatory factors each of them releases into the extracellular matrix in the course of AD. Neurons, blue. Astrocytes, green. Oligodendrocytes, yellow. Microglia, black. Endothelial cells (ECs), red. Monocytes, colorless. A black arrow indicates the migration of a monocyte into the nervous tissue. Senile plaques, ## Aβs. Most of the abbreviations as in the text. CHM, chemokines. PICs, proinflammatory cytokines. CaSR, calcium-sensing receptor. Bottom: Schematic diagram of the reciprocal interactions between the three main neural cell types involved in Alzheimer-related neuroinflammation. The bidirectional interaction with amyloid senile plaques is also indicated.
Figure 2
Figure 2
A schematic representation of some of the main PRRs and their signaling pathways involved in AD’s neuroinflammation. The cell represented could belong to any neural cell type. Aβs, soluble and/or fibrillar amyloid-β peptides; FPR2, formyl peptide receptor 2; IP3, inositol triphosphate; LT, lethal toxin; , upregulation; , downregulation. For further details and abbreviations see the text.

References

    1. Prince M.J., Wimo A., Guerchet M.M., Ali G.C., Wu Y.-T., Prina M. World Alzheimer Report 2015. The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. [(accessed on 21 September 2015)]; Available online: https://www.alzint.org.
    1. Knopman D.S., Haeberlein S.B., Carrillo M.C., Hendrix J.A., Kerchner G., Margolin R., Maruff P., Miller D.S., Tong G., Tome M.B., et al. The National Institute on Aging and the Alzheimer’s Association Research framework for Alzheimer’s disease: Perspectives from the research roundtable. Alzheimers Dement. 2018;14:563–575. doi: 10.1016/j.jalz.2018.03.002. - DOI - PMC - PubMed
    1. Labzin L.I., Heneka M.T., Latz E. Innate immunity and neurodegeneration. Annu. Rev. Med. 2018;69:437–449. doi: 10.1146/annurev-med-050715-104343. - DOI - PubMed
    1. Becher B., Spath S., Goverman J. Cytokine networks in neuroinflammation. Nat. Rev. Immunol. 2017;17:49–59. doi: 10.1038/nri.2016.123. - DOI - PubMed
    1. Gouras G.K., Olsson T.T., Hansson O. β-Amyloid pep–tides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics. 2015;12:3–11. doi: 10.1007/s13311-014-0313-y. - DOI - PMC - PubMed

Substances